Search results for "Bone Marrow"

showing 10 items of 538 documents

Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma

2016

Purpose To compare whole-body MRI (WB-MRI) with diffusion-weighted imaging (DWI), FDG-PET/CT, and bone marrow biopsy (BMB), for the evaluation of bone marrow involvement (BMI) in patients with newly diagnosed lymphoma. Materials and Methods This retrospective study was approved by our Institutional Review Board. Two independent radiologists and one nuclear medicine specialist reviewed all WB-MRI and FDG-PET/CT scans prospectively performed on 104 patients with newly diagnosed lymphoma (53 males; 47 Hodgkin; mean age: 44 years; range, 15–86 years) between 2013 and 2015. The delay between imaging scans and BMBs was up to 10 days. The diagnostic accuracy of WB-MRI (1.5 Tesla MR scanner, with T…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryMagnetic resonance imagingRetrospective cohort studyNewly diagnosedmedicine.diseaseInstitutional review board030218 nuclear medicine & medical imagingLymphoma03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureCohen's kappa030220 oncology & carcinogenesisBiopsyMedicineRadiology Nuclear Medicine and imagingBone marrowRadiologybusinessNuclear medicineJournal of Magnetic Resonance Imaging
researchProduct

Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Societ…

2005

Patients undergoing allogeneic stem cell transplantation are at high risk for infection with a variety of pathogens during different phases of the procedure. Bacteria and fungi predominate the first phase until engraftment. During the second phase, from engraftment to about day 100, major infectious problems are caused by fungi and cytomegalovirus. Both pathogens remain important under continued immunosuppression, however, in the late post-transplantation period infections with encapsulated bacteria may become a problem. In this review the Infectious Diseases Working Party of the DGHO gives recommendations for prophylaxis of infections under allogeneic stem cell transplantation with drugs a…

medicine.medical_specialtymedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationNeutropenia03 medical and health sciences0302 clinical medicineAnti-Infective AgentsmedicineHumansTransplantation HomologousInfection controlAntibiotic prophylaxisIntensive care medicineBone Marrow TransplantationInfection Controlbusiness.industryImmunosuppressionHematologyAntibiotic ProphylaxisAntimicrobialmedicine.disease3. Good healthTransplantationOncology030220 oncology & carcinogenesisImmunologyPreventive Medicinebusiness030215 immunologyAnnals of Oncology
researchProduct

Polypeptides controlling hematopoietic blood cell development and activation

1989

Colony-stimulating factors (CSFs) have entered the clinical arena. Several investigators have explored, in first clinical phase I studies, different routes of administration to define the optimum biological dose, maximum tolerated dose, toxicity, and pharmacokinetics of these reagents. It has been demonstrated that recombinant human (rh) granulocyte-macrophage CSF (GM-CSF) and granulocyte CSF (G-CSF) can be safely administered over a broad dose range to increase number of circulating granulocytes in man. More recently, GM-CSF and G-CSF have been involved in phase Ib/II studies to assess the granulopoietic responses of patients with granulocytopenia due to various underlying disease states i…

medicine.medical_specialtymedicine.medical_treatmentGranulocyteCyclic neutropeniaColony-Stimulating FactorsBone MarrowInternal medicinemedicineHumansAplastic anemiaChemotherapyHematologybusiness.industryHematologyGeneral MedicineHematopoietic Stem Cellsmedicine.diseaseHematopoiesisGranulocyte colony-stimulating factorHaematopoiesisGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureImmunologyDrug EvaluationPeptidesbusinessmedicine.drugBlut
researchProduct

Bone marrow evaluation according to the PVSG and WHO criteria in 90 essential thrombocythemia (ET) patients treated with PEG interferon alpha-2b. Pre…

2005

Abstract Ninety ET patients diagnosed according to the PVSG criteria were enrolled in a phase II study (sponsored by the Schering-Plough Company) designed to evaluate the efficacy, safety and tolerability of a two years treatment with PEG Interferon alpha-2 b (PEG Intron). The patients, observed in 16 Italian Centres belonging to the GIMEMA Cooperative Group and judged at high risk, had been previously treated with cytoreductive (97%) and antiplatelet (91%) drugs. At the study start the patients, 60 F and 30 M, mean age 45 years, showed splenomegaly in 22% of cases. The Hematological Response (HR: PLT<500 x109/L) was observed in 64/81 (79%) and 48/55 (87%) of the patients on PEG Intr…

medicine.medical_specialtythrombocythemia (ET) patientsImmunologyEssential Thrombocythemia (ET); PEG Interferon alpha-2b.Phases of clinical researchAlpha (ethology)BiochemistryGastroenterologyPEG Interferon alpha-2bFibrosisInternal medicinePEG ratioBiopsyMedicineEssential Thrombocythemia (ET)medicine.diagnostic_testbusiness.industryEssential thrombocythemiaCell BiologyHematologymedicine.diseaseSurgerymedicine.anatomical_structureTolerabilityBone marrow evaluationBone marrowbusiness
researchProduct

Immunologic microenvironment and personalized treatment in multiple myeloma.

2013

Introduction: Multiple myeloma (MM) is characterized by generalized immune suppression and increased susceptibility to infections and secondary malignancies. Malignant plasma cells (PCs) modulate the bone marrow microenvironment to favor their own survival and proliferation. These events lead to a severe deregulation of immune effectors. Extensive studies have been conducted to unveil the mechanisms through which MM cells negatively modulate immunity and to develop therapeutical approaches for restoring an efficient anti-MM immune response. Areas covered: This review article covers both the immunosuppressive effects exerted by MM and the immunomodulatory potential of novel anti-MM agents. A…

medicine.medical_treatmentClinical BiochemistryAntineoplastic AgentsImmune systemImmunityDrug DiscoveryTumor MicroenvironmentMedicineHumansPrecision MedicineMultiple myelomaBone marrow microenvironmentPharmacologyTumor microenvironmentbusiness.industryImmunotherapymedicine.diseaseReview articlemedicine.anatomical_structurePersonalized treatmentImmune SystemImmunologyBone marrowPersonalized medicineImmunotherapybusinessMultiple MyelomaExpert opinion on biological therapy
researchProduct

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation

2014

Graft-versus-host disease (GVHD) is a frequent life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT) and induced by donor-derived T cells that become activated by host antigen-presenting cells. To address the relevance of host dendritic cell (DC) populations in this disease, we used mouse strains deficient in CD11c(+) or CD8α(+) DC populations in a model of acute GVHD where bone marrow and T cells from BALB/c donors were transplanted into C57BL/6 hosts. Surprisingly, a strong increase in GVHD-related mortality was observed in the absence of CD11c(+) cells. Likewise, Batf3-deficient (Batf3(-/-)) mice that lack CD8α(+) DCs also displayed a strongly incr…

medicine.medical_treatmentGraft vs Host DiseasePriming (immunology)CD11cHematopoietic stem cell transplantationchemical and pharmacologic phenomenaHematopoietic stem cell transplantationCD8-Positive T-LymphocytesBiologyGraft-versus-host diseaseDendritic cellsMiceimmune system diseasesBATF3medicineAnimalsTransplantation HomologousBone Marrow TransplantationMice Inbred BALB CTransplantationPeripheral toleranceHematologyDendritic cellmedicine.diseaseMice Inbred C57BLsurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureImmunologyBone marrowCD8Biology of Blood and Marrow Transplantation
researchProduct

Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1.

2000

Abstract Recently, the Th2-type cytokine IL-9 was identified by genetic mapping analyses as a key mediator that determines the susceptibility to asthma. This has been further supported by data from IL-9-transgenic mice in which the overexpression of IL-9 in the lung causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. In an accompanying paper, we demonstrate that murine bone marrow-derived mast cells (BMMC) after stimulation with either ionomycin, a combination of ionomycin and IL-1, or via IgE-Ag complexes and IL-1 are very potent producers of IL-9. Herein we show that a dramatic increase of IL-9 production is observed when BMMC activated with ionomycin/IL-…

medicine.medical_treatmentImmunologyEndogenyStem cell factorBone Marrow CellsBiologychemistry.chemical_compoundMiceAdjuvants ImmunologicmedicineImmunology and AllergyAnimalsMast CellsRNA MessengerReporter geneMice Inbred BALB CStem Cell FactorInterleukin-9TransfectionMolecular biologyInterleukin-10Interleukin 10medicine.anatomical_structureCytokinechemistryGene Expression RegulationIonomycinImmunologyBone marrow5' Untranslated RegionsInterleukin-1Journal of immunology (Baltimore, Md. : 1950)
researchProduct

A Role for Leukocyte-Derived IL-1RA in DC Homeostasis Revealed by Increased Susceptibility of IL-1RA-Deficient Mice to Cutaneous Leishmaniasis

2011

Dendritic cell (DC)-derived IL-1α/β plays a critical role in the induction of T helper type 1 (Th1)-dependent immunity against Leishmania . DCs from susceptible BALB/c mice produce less IL-1α/β when compared with resistant C57BL/6 mice, contributing to aberrant Th2 development and ultimate death of infected mice. We have extended our studies of the role of IL-1 in leishmaniasis using IL-1RA -/- BALB/c mice that are characterized by upregulated IL-1 receptor signaling. Unexpectedly, infection of IL-1RA -/- mice led to significantly worsened disease outcome with larger lesions, dramatically higher parasite burdens, and decreased IFN-γ production by antigen-specific T cells. We determined that…

medicine.medical_treatmentLeishmaniasis CutaneousBone Marrow CellsDermatologyBiochemistryArticleImmunophenotypingMicePhagocytosisCutaneous leishmaniasisDownregulation and upregulationImmunitymedicineAnimalsLeishmania majorMolecular BiologyLeishmania majorMice Inbred BALB CbiologyLeishmaniasisDendritic CellsDendritic cellCell BiologyTh1 Cellsmedicine.diseasebiology.organism_classificationLeishmaniaInterleukin-12Mice Mutant StrainsInterleukin 1 Receptor Antagonist ProteinCytokineImmunologyDisease SusceptibilityInterleukin-1Journal of Investigative Dermatology
researchProduct

Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (int…

1990

We have previously shown that certain bone marrow-derived mast cell (BMMC) lines proliferate in response to a mast cell growth-enhancing activity (MEA) that is distinct from interleukin (IL) 3 and IL 4. Here we provide evidence that MEA is identical with the recently cloned mouse T cell growth factor P40. The evidence is as follows: (a) recombinant P40 displayed all the biological activities ascribed to MEA: it supported the growth of MEA-sensitive BMMC lines, it induced IL 6 secretion by these cells, and it enhanced survival of primary mast cell cultures; (b) highly purified MEA stimulated the growth of P40-dependent cell lines; (c) a rabbit monospecific antiserum directed against P40 spec…

medicine.medical_treatmentT-LymphocytesImmunologyBone Marrow CellsBiologyIn Vitro TechniquesBinding CompetitiveMicemedicineImmunology and AllergyAnimalsInterleukin 9Mast CellsGrowth SubstancesInterleukin 4Cell growthGrowth factorImmune SeraInterleukinsInterleukin-9Interleukinfood and beveragesMast cellCell biologyCytokinemedicine.anatomical_structureCell cultureImmunologyEuropean journal of immunology
researchProduct

CD40 activity on mesenchymal cells negatively regulates OX40L to maintain bone marrow immune homeostasis under stress conditions

2021

BackgroundWithin the bone marrow (BM), mature T cells are maintained under homeostatic conditions to facilitate proper hematopoietic development. This homeostasis depends upon a peculiar elevated frequency of regulatory T cells (Tregs) and immune regulatory activities from BM-mesenchymal stem cells (BM-MSCs). In response to BM transplantation (BMT), the conditioning regimen exposes the BM to a dramatic induction of inflammatory cytokines and causes an unbalanced T-effector (Teff) and Treg ratio. This imbalance negatively impacts hematopoiesis, particularly in regard to B-cell lymphopoiesis that requires an intact cross-talk between BM-MSCs and Tregs. The mechanisms underlying the ability of…

mesenchymal cellAdultMaleCancer ResearchTransplantation ConditioningT cellbone marrow transplantationImmunologyBone Marrow CellsOX40 LigandBiologySettore MED/08 - Anatomia PatologicaLymphocyte ActivationMesenchymal Stem Cell TransplantationT-Lymphocytes RegulatoryMiceYoung AdultImmune systemBone MarrowStress PhysiologicalmedicineCD40AnimalsHomeostasisHumansImmunology and AllergyLymphopoiesisCD40 AntigensOriginal ResearchAgedCD40B-cell developmentMesenchymal Stem Cellshemic and immune systemsRC581-607Middle AgedOX40LCell biologyTransplantationHaematopoiesismedicine.anatomical_structureGene Expression Regulationbiology.proteinFemaleBone marrowImmunologic diseases. AllergyStem cellB-cell developmentbone marrow transplantation CD40 mesenchymal cell OX40L
researchProduct